Genetic background, gender, age, body temperature, and arterial blood pH have a major impact on myocardial infarct size in the mouse and need to be carefully measured and/or taken into account: Results of a comprehensive analysis of determinants of infarct size in 1,074 mice

Basic Research in Cardiology

Volumn 107, Issue 5, 2012, Pages

  Guo, Yiru ^a   Flaherty, Michael P ^a   Wu, Wen Jian ^a   Tan, Wei ^a   Zhu, Xiaoping ^a   Li, Qianhong ^a   Bolli, Roberto ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Age; Blood transfusion; Cardioprotection; Core body temperature; Gender; Ischemia reperfusion injury; Myocardial infarction; PH; Strain

Indexed keywords

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PH; ARTICLE; BLEEDING; BODY TEMPERATURE; CONTROLLED STUDY; CRYSTALLOID; EARLY INTERVENTION; FEMALE; FLUID THERAPY; GENDER; GENETIC SUSCEPTIBILITY; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART PROTECTION; HEREDITY; HYPOTHERMIA; MALE; MOUSE; NONHUMAN; REPERFUSION INJURY; RESPIRATORY ACIDOSIS; SEX DIFFERENCE; STRAIN DIFFERENCE; THERAPY DELAY; THERAPY EFFECT; TREATMENT OUTCOME; ANIMAL; BLOOD TRANSFUSION; GENETICS; HEART INFARCTION; HEMODYNAMICS; MOUSE STRAIN; PATHOPHYSIOLOGY; PH; SPECIES DIFFERENCE;

AGE FACTORS; ANIMALS; BLOOD TRANSFUSION; BODY TEMPERATURE; FEMALE; HEMODYNAMICS; HYDROGEN-ION CONCENTRATION; MALE; MICE; MICE, INBRED STRAINS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; SEX FACTORS; SPECIES SPECIFICITY;

EID: 84864485010     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-012-0288-y     Document Type: Article

References (71)

1. Abdullah I, Lepore JJ, Epstein JA, Parmacek MS, Gruber PJ (2005) MRL mice fail to heal the heart in response to ischemiareperfusion injury. Wound Repair Regen 13:205-208. doi: 10.1111/j.1067-1927.2005.130212.x
2. Akdemir B, Kara S, Polat K, Guven A, Gunes S (2008) Ensemble adaptive network-based fuzzy inference system with weighted arithmetical mean and application to diagnosis of optic nerve disease from visual-evoked potential signals. Artif Intell Med 43:141-149. doi:10.1016/j.artmed.2008.03.007
3. Benjamin IJ, Guo Y, Srinivasan S, Boudina S, Taylor RP, Rajasekaran NS, Gottlieb R, Wawrousek EF, Abel ED, Bolli R (2007) CRYAB and HSPB2 deficiency alters cardiac metabolism and paradoxically confers protection against myocardial ischemia in aging mice. Am J Physiol Heart Circ Physiol 293:H3201-H3209. doi:10.1152/ajpheart.01363.2006
4. Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R (2010) Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol 105:771-785. doi:10.1007/s00395-010-0124-1
5. Boengler K, Schulz R, Heusch G (2009) Loss of cardioprotection with ageing. Cardiovasc Res 83:247-261. doi:10.1093/cvr/ cvp033
6. Bolli R (2007) Preconditioning: A paradigm shift in the biology of myocardial ischemia. Am J Physiol Heart Circ Physiol 292:H19-H27. doi:10.1152/ajpheart.00712.2006
7. Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, Lathrop DA, NHLBI working group on the translation of therapies for protecting the heart from ischemia (2004) Myocardial protection at a crossroads: The need for translation into clinical therapy. Circ Res 95:125-134. doi:10.1161/01.RES.0000137171.97172. d7
8. Bolli R, Marban E (1999) Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 79:609-634
9. Cavasin MA, Tao ZY, Yu AL, Yang XP (2006) Testosterone enhances early cardiac remodeling after myocardial infarction, causing rupture and degrading cardiac function. Am J Physiol Heart Circ Physiol 290:H2043-H2050. doi:10.1152/ajpheart. 01121.2005
10. Chien GL, Wolff RA, Davis RF, van Winkle DM (1994) "Normothermic range" temperature affects myocardial infarct size. Cardiovasc Res 28:1014-1017
11. Dawn B, Guo Y, Rezazadeh A, Huang Y, Stein AB, Hunt G, Tiwari S, Varma J, Gu Y, Prabhu SD, Kajstura J, Anversa P, Ildstad ST, Bolli R (2006) Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function. Circ Res 98:1098-1105. doi:10.1161/01.RES.0000218454.76784.66
12. Dawn B, Guo Y, Rezazadeh A, Wang OL, Stein AB, Hunt G, Varma J, Xuan YT, Wu WJ, Tan W, Zhu X, Bolli R (2004) Tumor necrosis factor-alpha does not modulate ischemia/reperfusion injury in naive myocardium but is essential for the development of late preconditioning. J Mol Cell Cardiol 37:51-61. doi:10.1016/j.yjmcc.2004.03.012
13. Dawn B, Tiwari S, Kucia MJ, Zuba-Surma EK, Guo Y, Sanganalmath SK, Abdel-Latif A, Hunt G, Vincent RJ, Taher H, Reed NJ, Ratajczak MZ, Bolli R (2008) Transplantation of bone marrow-derived very small embryonic-like stem cells attenuates left ventricular dysfunction and remodeling after myocardial infarction. Stem Cells 26:1646-1655. doi:10.1634/stemcells. 2007-0715
14. Dawn B, Xuan YT, Guo Y, Rezazadeh A, Stein AB, Hunt G, Wu WJ, Tan W, Bolli R (2004) IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res 64:61-71. doi:10.1016/ j.cardiores.2004.05.011
15. Duncker DJ, Klassen CL, Ishibashi Y, Herrlinger SH, Pavek TJ, Bache RJ (1996) Effect of temperature on myocardial infarction in swine. Am J Physiol 270:H1189-H1199
16. Flaherty MP, Guo Y, Tiwari S, Rezazadeh A, Hunt G, Sanganalmath SK, Tang XL, Bolli R, Dawn B (2008) The role of TNF-alpha receptors p55 and p75 in acute myocardial ischemia/ reperfusion injury and late preconditioning. J Mol Cell Cardiol 45:735-741. doi:10.1016/j.yjmcc.2008.08.014
17. Gao XM, Xu Q, Kiriazis H, Dart AM, Du XJ (2005) Mouse model of post-infarct ventricular rupture: Time course, strain-and gender-dependency, tensile strength, and histopathology. Cardiovasc Res 65:469-477. doi:10.1016/j.cardiores.2004.10.014
18. Gerlai R (1996) Gene-targeting studies of mammalian behavior: Is it the mutation or the background genotype? Trends Neurosci 19:177-181
19. Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD (1996) Myocardial protection by brief ischemia in noncardiac tissue. Circulation 94:2193-2200
20. Gorog DA, Tanno M, Kabir AM, Kanaganayagam GS, Bassi R, Fisher SG, Marber MS (2003) Varying susceptibility to myocardial infarction among C57BL/6 mice of different genetic background. J Mol Cell Cardiol 35:705-708
21. Guo Y, Bao W, Wu WJ, Shinmura K, Tang XL, Bolli R (2000) Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice. Basic Res Cardiol 95:479-484
22. Guo Y, Bao W, Wu WJ, Tang XL, Bolli R (1999) Nitric oxide donors induce late preconditioning against myocardial infarction in mice. J Mol Cell Cardiol 31:A11-A19
23. Guo Y, Bolli R, Bao W, Wu WJ, Black RG, Murphree SS, Salvatore CA, Jacobson MA, Auchampach JA (2001) Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. J Mol Cell Cardiol 33:825-830. doi:10.1006/jmcc.2001.1338
24. Guo Y, Jones WK, Xuan YT, Tang XL, Bao W, Wu WJ, Han H, Laubach VE, Ping P, Yang Z, Qiu Y, Bolli R (1999) The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci USA 96:11507-11512
25. Guo Y, Li Q, Wu WJ, Tan W, Zhu X, Mu J, Bolli R (2008) Endothelial nitric oxide synthase is not necessary for the early phase of ischemic preconditioning in the mouse. J Mol Cell Cardiol 44:496-501. doi:10.1016/j.yjmcc.2008.01.003
26. Guo Y, Sanganalmath SK, Wu W, Zhu X, Huang Y, Tan W, Ildstad ST, Li Q, Bolli R (2012) Identification of inducible nitric oxide synthase in peripheral blood cells as a mediator of myocardial ischemia/reperfusion injury. Basic Res Cardiol 107:253. doi:10.1007/s00395-012-0253-9
27. Guo Y, Stein AB, Wu WJ, Tan W, Zhu X, Li QH, Dawn B, Motterlini R, Bolli R (2004) Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo. Am J Physiol Heart Circ Physiol 286:H1649-H1653. doi: 10.1152/ajpheart.00971.2003
28. Guo Y, Stein AB, Wu WJ, Zhu X, Tan W, Li Q, Bolli R (2005) Late preconditioning induced by NO donors, adenosine A1 receptor agonists, and delta1-opioid receptor agonists is mediated by iNOS. Am J Physiol Heart Circ Physiol 289:H2251-H2257. doi:10.1152/ajpheart.00341.2005
29. Guo Y, Tang XL, Bao W, Bolli R (2000) How to produce infarction in the mouse in vivo. In: Downey JM (ed) The ISHR handbook of experimental of laboratory procedures (HELP). http://www.ishrworld.org/
30. Guo Y, Wu WJ, Qiu Y, Tang XL, Yang Z, Bolli R (1998) Demonstration of an early and a late phase of ischemic preconditioning in mice. Am J Physiol 275:H1375-H1387
31. Guo Y, Wu WJ, Zhu X, Tan W, Bolli R (2003) The development of the early phase of ischemic preconditioning in mice is not strain dependent. J Mol Cell Cardiol 35:A47-P110
32. Hale SL, Kloner RA (1999) Ischemic preconditioning and myocardial hypothermia in rabbits with prolonged coronary artery occlusion. Am J Physiol 276:H2029-H2034
33. Hale SL, Kloner RA (1997) Myocardial temperature in acute myocardial infarction: Protection with mild regional hypothermia. Am J Physiol 273:H220-H227
34. Halestrap A (2005) Biochemistry: A pore way to die. Nature 434:578-579. doi:10.1038/434578a
35. Hausenloy DJ, Baxter G, Bell R, Botker HE, Davidson SM, Downey J, Heusch G, Kitakaze M, Lecour S, Mentzer R, Mocanu MM, Ovize M, Schulz R, Shannon R, Walker M, Walkinshaw G, Yellon DM (2010) Translating novel strategies for cardioprotection: The Hatter workshop recommendations. Basic Res Cardiol 105:677-686. doi:10.1007/s00395-010-0121-4
36. Heger J, Godecke A, Flogel U, Merx MW, Molojavyi A, Kuhn-Velten WN, Schrader J (2002) Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ Res 90:93-99
37. Heusch G, Buchert A, Feldhaus S, Schulz R (2006) No loss of cardioprotection by postconditioning in connexin 43-deficient mice. Basic Res Cardiol 101:354-356. doi:10.1007/s00395-006-0589-0
38. Higuchi Y, McTiernan CF, Frye CB, McGowan BS, Chan TO, Feldman AM (2004) Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. Circulation 109:1892-1897. doi:10.1161/ 01.CIR.0000124227.00670.AB
39. Ho HT, Chung SK, Law JW, Ko BC, Tam SC, Brooks HL, Knepper MA, Chung SS (2000) Aldose reductase-deficient mice develop nephrogenic diabetes insipidus. Mol Cell Biol 20:5840-5846
40. Hutter JJ, Mestril R, Tam EK, Sievers RE, Dillmann WH, Wolfe CL (1996) Overexpression of heat shock protein 72 in transgenic mice decreases infarct size in vivo. Circulation 94:1408-1411
41. Jones WK, Flaherty MP, Tang XL, Takano H, Qiu Y, Banerjee S, Smith T, Bolli R (1999) Ischemic preconditioning increases iNOS transcript levels in conscious rabbits via a nitric oxidedependent mechanism. J Mol Cell Cardiol 31:1469-1481. doi: 10.1006/jmcc.1999.0983
42. Jung O, Marklund SL, Geiger H, Pedrazzini T, Busse R, Brandes RP (2003) Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: In vivo and ex vivo evidence from ecSOD-deficient mice. Circ Res 93:622-629. doi: 10.1161/01.RES.0000092140.81594.A8
43. Kleinbongard P, Heusch G, Schulz R (2010) TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther 127:295-314. doi:10.1016/j.pharmthera.2010. 05.002
44. Korff S, Riechert N, Schoensiegel F, Weichenhan D, Autschbach F, Katus HA, Ivandic BT (2006) Calcification of myocardial necrosis is common in mice. Virchows Arch 448:630-638. doi: 10.1007/s00428-005-0071-7
45. Lefer DJ, Bolli R (2011) Development of an NIH consortium for preclinical assessment of cardioprotective therapies (CAESAR): A paradigm shift in studies of infarct size limitation. J Cardiovasc Pharmacol Ther 16:332-339. doi:10.1177/1074248411414155
46. Lemasters JJ, Bond JM, Chacon E, Harper IS, Kaplan SH, Ohata H, Trollinger DR, Herman B, Cascio WE (1996) The pH paradox in ischemia-reperfusion injury to cardiac myocytes. EXS 76:99-114
47. Lesnefsky EJ, Gallo DS, Ye J, Whittingham TS, Lust WD (1994) Aging increases ischemia-reperfusion injury in the isolated, buffer-perfused heart. J Lab Clin Med 124:843-851
48. Li Q, Guo Y, Ou Q, Cui C, Wu WJ, Tan W, Zhu X, Lanceta LB, Sanganalmath SK, Dawn B, Shinmura K, Rokosh GD, Wang S, Bolli R (2009) Gene transfer of inducible nitric oxide synthase affords cardioprotection by upregulating heme oxygenase-1 via a nuclear factor-{kappa}B-dependent pathway. Circulation 120:1222-1230. doi:10.1161/CIRCULATIONAHA.108.778688
49. Li Q, Guo Y, Ou Q, Wu WJ, Chen N, Zhu X, Tan W, Yuan F, Dawn B, Luo L, Hunt GN, Bolli R (2011) Gene transfer as a strategy to achieve permanent cardioprotection II: RAAV-mediated gene therapy with heme oxygenase-1 limits infarct size 1 year later without adverse functional consequences. Basic Res Cardiol 106:1367-1377. doi:10.1007/s00395-011-0208-6
50. Li Q, Guo Y, Tan W, Ou Q, Wu WJ, Sturza D, Dawn B, Hunt G, Cui C, Bolli R (2007) Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway. Circulation 116:1577-1584. doi:10.1161/CIRCULATIONAHA.107.689810
51. Li Q, Guo Y, Tan W, Stein AB, Dawn B, Wu WJ, Zhu X, Lu X, Xu X, Siddiqui T, Tiwari S, Bolli R (2006) Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences. Am J Physiol Heart Circ Physiol 290:H584-H589. doi:10.1152/ajpheart.00855. 2005
52. Li Q, Guo Y, Wu WJ, Ou Q, Zhu X, Tan W, Yuan F, Chen N, Dawn B, Luo L, O'Brien E, Bolli R (2011) Gene transfer as a strategy to achieve permanent cardioprotection I: RAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences. Basic Res Cardiol 106:1355-1366. doi:10.1007/s00395-011-0207-7
53. Li Q, Guo Y, Xuan YT, Lowenstein CJ, Stevenson SC, Prabhu SD, Wu WJ, Zhu Y, Bolli R (2003) Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism. Circ Res 92:741-748. doi:10.1161/01.RES.0000065441.72685.29
54. Li TT, Larrucea S, Souza S, Leal SM, Lopez JA, Rubin EM, Nieswandt B, Bray PF (2004) Genetic variation responsible for mouse strain differences in integrin alpha 2 expression is associated with altered platelet responses to collagen. Blood 103:3396-3402. doi:10.1182/blood-2003-10-3721
55. Meldrum DR, Cleveland JC Jr, Cain BS, Meng X, Harken AH (1998) Increased myocardial tumor necrosis factor-alpha in a crystalloid-perfused model of cardiac ischemia-reperfusion injury. Ann Thorac Surg 65:439-443
56. Michael LH, Entman ML, Hartley CJ, Youker KA, Zhu J, Hall SR, Hawkins HK, Berens K, Ballantyne CM (1995) Myocardial ischemia and reperfusion: A murine model. Am J Physiol 269:H2147-H2154
57. Miller DL, Van Winkle DM (1999) Ischemic preconditioning limits infarct size following regional ischemia-reperfusion in in situ mouse hearts. Cardiovasc Res 42:680-684
58. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A, Oh-ishi S, Narumiya S (1997) Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388:678-682. doi:10.1038/41780
59. Ning XH, Xu CS, Song YC, Xiao Y, Hu YJ, Lupinetti FM, Portman MA (1998) Hypothermia preserves function and signaling for mitochondrial biogenesis during subsequent ischemia. Am J Physiol 274:H786-H793
60. Sanganalmath SK, Abdel-Latif A, Bolli R, Xuan YT, Dawn B (2011) Hematopoietic cytokines for cardiac repair: Mobilization of bone marrow cells and beyond. Basic Res Cardiol 106:709-733. doi:10.1007/s00395-011-0183-y
61. Sanganalmath SK, Stein AB, Guo Y, Tiwari S, Hunt G, Vincent RJ, Huang Y, Rezazadeh A, Ildstad ST, Dawn B, Bolli R (2009) The beneficial effects of postinfarct cytokine combination therapy are sustained during long-term follow-up. J Mol Cell Cardiol 47:528-535. doi:10.1016/j.yjmcc.2009.07.009
62. Schwartz LM, Verbinski SG, Vander Heide RS, Reimer KA (1997) Epicardial temperature is a major predictor of myocardial infarct size in dogs. J Mol Cell Cardiol 29:1577-1583. doi: 10.1006/jmcc.1997.0391
63. Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E, Downey J, Gibbons RJ, Gottlieb RA, Heusch G, Jennings RB, Lefer DJ, Mentzer RM, Murphy E, Ovize M, Ping P, Przyklenk K, Sack MN, Vander Heide RS, Vinten-Johansen J, Yellon DM, National heart L, Blood Institute NIoH, (2011) New horizons in cardioprotection: Recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation 124:1172-1179. doi:10.1161/CIRCULATIONAHA.111.032698
64. Stein AB, Guo Y, Tan W, Wu WJ, Zhu X, Li Q, Luo C, Dawn B, Johnson TR, Motterlini R, Bolli R (2005) Administration of a CO-releasing molecule induces late preconditioning against myocardial infarction. J Mol Cell Cardiol 38:127-134. doi: 10.1016/j.yjmcc.2004.10.006
65. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, Dunson DB, Rogan EG, Morham SG, Smart RC, Langenbach R (2002) Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 62:3395-3401
66. van den Doel MA, Gho BC, Duval SY, Schoemaker RG, Duncker DJ, Verdouw PD (1998) Hypothermia extends the cardioprotection by ischaemic preconditioning to coronary artery occlusions of longer duration. Cardiovasc Res 37:76-81
67. Wang GW, Guo Y, Vondriska TM, Zhang J, Zhang S, Tsai LL, Zong NC, Bolli R, Bhatnagar A, Prabhu SD (2008) Acrolein consumption exacerbates myocardial ischemic injury and blocks nitric oxide-induced PKC epsilon signaling and cardioprotection. J Mol Cell Cardiol 44:1016-1022. doi:10.1016/j.yjmcc.2008.03. 020
68. Xuan YT, Guo Y, Han H, Zhu Y, Bolli R (2001) An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci USA 98:9050-9055. doi:10.1073/pnas.161283798
69. Xuan YT, Guo Y, Zhu Y, Wang OL, Rokosh G, Bolli R (2007) Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSersignal transducers and activators of transcription 1/3 pathway. Circulation 116:535-544. doi:10.1161/CIRCULATIONAHA. 107.689471
70. Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:1121-1135. doi:10.1056/NEJMra071667
71. Zuba-Surma EK, Kucia M, Dawn B, Guo Y, Ratajczak MZ, Bolli R (2008) Bone marrow-derived pluripotent very small embryonic-like stem cells (VSELs) are mobilized after acute myocardial infarction. J Mol Cell Cardiol 44:865-873. doi:10.1016/ j.yjmcc.2008.02.279